CVM GFI #197 记录电子数据文件和统计分析程序

2021-10-01 美国食品和药品监督管理局 FDA

对于新的动物药物申请,FDA 要求提供完整的调查报告,这些调查表明药物使用安全和有效[联邦食品、药品和化妆品法案第 512(b)(1)(A)条( FD&C 法案)]。此外,FD&C 法

中文标题:

CVM GFI #197 记录电子数据文件和统计分析程序

英文标题:

CVM GFI #197 Documenting Electronic Data Files and Statistical Analysis Programs

发布日期:

2021-10-01

简要介绍:

对于新的动物药物申请,FDA 要求提供完整的调查报告,这些调查表明药物使用安全和有效[联邦食品、药品和化妆品法案第 512(b)(1)(A)条( FD&C 法案)]。此外,FD&C 法案第 512(n)(1)(E) 节要求批准新动物药的简短申请包含信息,以证明新动物药与已批准的新动物药生物等效。

为支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。对于包含电子数据文件的每项研究,CVM 需要有关数据生成过程的文档和进行的统计分析的信息,以便审查提交并验证证据的质量和细节是否足以支持动物药物申请。一份充分记录的提交应包括可读的电子数据文件、数据处理方式的描述以及用于支持您的结论的统计分析的描述。

您的文档应清楚地描述收集数据的整个过程,包括数据所有更改的记录,从从转录的病例报告表或电子数据捕获系统创建的电子数据文件到完成的统计分析这构成了您研究结论的基础。要了解您编制数据和进行统计分析的过程,CVM 需要了解每个数据文件的内容、处理所有电子数据文件进行分析的计算机程序以及执行统计分析的程序。本指南描述了应提交给 CVM 的信息以及 FSR 和电子数据集,以及有关如何组织和完成自述文件以描述数据集和分析的建议,以及有关统计程序的其他建议。

相关资料下载:
[AttachmentFileName(sort=1, fileName=1.pdf)] GetToolGuiderByIdResponse(projectId=1, id=849fb1c00222e346, title=CVM GFI #197 记录电子数据文件和统计分析程序, enTitle=CVM GFI #197 Documenting Electronic Data Files and Statistical Analysis Programs, guiderFrom=FDA, authorId=0, author=, summary=对于新的动物药物申请,FDA 要求提供完整的调查报告,这些调查表明药物使用安全和有效[联邦食品、药品和化妆品法案第 512(b)(1)(A)条( FD&C 法案)]。此外,FD&C 法, cover=, journalId=0, articlesId=null, associationId=486, associationName=美国食品和药品监督管理局, associationIntro=美国食品和药品监督管理局是美国公共卫生及服务部的一个代理商,其由委员会办公室和4个监督核心功能理事机构组成。, copyright=0, guiderPublishedTime=Fri Oct 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span class="VIiyi" lang="zh-CN"><span class="JLqJ4b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0" data-number-of-phrases="1">对于新的动物药物申请,FDA 要求提供完整的调查报告,这些调查表明药物使用安全和有效[联邦食品、药品和化妆品法案第 512(b)(1)(A)条( FD&amp;C 法案)]。此外,FD&amp;C 法案第 512(n)(1)(E) 节要求批准新动物药的简短申请包含信息,以证明新动物药与已批准的新动物药生物等效。 </span></span></p> <p><span class="VIiyi" lang="zh-CN"><span class="JLqJ4b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0" data-number-of-phrases="1">为支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。对于包含电子数据文件的每项研究,CVM 需要有关数据生成过程的文档和进行的统计分析的信息,以便审查提交并验证证据的质量和细节是否足以支持动物药物申请。一份充分记录的提交应包括可读的电子数据文件、数据处理方式的描述以及用于支持您的结论的统计分析的描述。 </span></span></p> <p><span class="VIiyi" lang="zh-CN"><span class="JLqJ4b" data-language-for-alternatives="zh-CN" data-language-to-translate-into="en" data-phrase-index="0" data-number-of-phrases="1">您的文档应清楚地描述收集数据的整个过程,包括数据所有更改的记录,从从转录的病例报告表或电子数据捕获系统创建的电子数据文件到完成的统计分析这构成了您研究结论的基础。要了解您编制数据和进行统计分析的过程,CVM 需要了解每个数据文件的内容、处理所有电子数据文件进行分析的计算机程序以及执行统计分析的程序。本指南描述了应提交给 CVM 的信息以及 FSR 和电子数据集,以及有关如何组织和完成自述文件以描述数据集和分析的建议,以及有关统计程序的其他建议。</span></span></p>, tagList=[TagDto(tagId=15, tagName=统计)], categoryList=[CategoryDto(categoryId=67, categoryName=研究设计与统计, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=30, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=725, appHits=8, showAppHits=0, pcHits=191, showPcHits=717, likes=0, shares=0, comments=5, approvalStatus=1, publishedTime=Sun Oct 24 19:38:51 CST 2021, publishedTimeString=2021-10-01, pcVisible=1, appVisible=1, editorId=4754896, editor=小小医者, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=小小医者, createdTime=Fri Oct 22 13:04:11 CST 2021, updatedBy=4754896, updatedName=小小医者, updatedTime=Sat Jan 06 18:28:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=1.pdf)])
1.pdf
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1082284, encodeId=8a871082284bb, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Tue Dec 21 00:38:58 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082283, encodeId=04501082283ac, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Tue Dec 21 00:38:55 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063565, encodeId=8b0310635658a, content=新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 21:03:02 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063541, encodeId=640a10635412c, content=为支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR), beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 20:57:02 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063539, encodeId=8bf5106353925, content=支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 20:56:39 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
    2021-12-21 一己怀

    谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1082284, encodeId=8a871082284bb, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Tue Dec 21 00:38:58 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082283, encodeId=04501082283ac, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Tue Dec 21 00:38:55 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063565, encodeId=8b0310635658a, content=新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 21:03:02 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063541, encodeId=640a10635412c, content=为支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR), beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 20:57:02 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063539, encodeId=8bf5106353925, content=支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 20:56:39 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
    2021-12-21 一己怀

    谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1082284, encodeId=8a871082284bb, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Tue Dec 21 00:38:58 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082283, encodeId=04501082283ac, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Tue Dec 21 00:38:55 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063565, encodeId=8b0310635658a, content=新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 21:03:02 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063541, encodeId=640a10635412c, content=为支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR), beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 20:57:02 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063539, encodeId=8bf5106353925, content=支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 20:56:39 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
    2021-10-24 ms9000000212834100

    新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1082284, encodeId=8a871082284bb, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Tue Dec 21 00:38:58 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082283, encodeId=04501082283ac, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Tue Dec 21 00:38:55 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063565, encodeId=8b0310635658a, content=新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 21:03:02 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063541, encodeId=640a10635412c, content=为支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR), beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 20:57:02 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063539, encodeId=8bf5106353925, content=支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 20:56:39 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
    2021-10-24 ms9000000212834100

    为支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1082284, encodeId=8a871082284bb, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Tue Dec 21 00:38:58 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082283, encodeId=04501082283ac, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Tue Dec 21 00:38:55 CST 2021, time=2021-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063565, encodeId=8b0310635658a, content=新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 21:03:02 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063541, encodeId=640a10635412c, content=为支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR), beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 20:57:02 CST 2021, time=2021-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1063539, encodeId=8bf5106353925, content=支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a54e5645039, createdName=ms9000000212834100, createdTime=Sun Oct 24 20:56:39 CST 2021, time=2021-10-24, status=1, ipAttribution=)]
    2021-10-24 ms9000000212834100

    支持新的动物药物申请而向 CVM 提交的材料通常包括一项或多项研究的最终研究报告 (FSR)。

    0